PDCD1 and melanoma: Regarding TIM-3 ligands, binding of HMGB1 dysregulates DCs’ activation and function [90], while CAECAM1 was found to be upregulated in metastatic specimens from melanoma patients with disease progression under PD-1 inhibition [91].